LFST Relative Valuation
LFST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LFST is overvalued; if below, it's undervalued.
Historical Valuation
LifeStance Health Group Inc (LFST) is now in the Fair zone, suggesting that its current forward PS ratio of 1.28 is considered Fairly compared with the five-year average of -31.15. The fair price of LifeStance Health Group Inc (LFST) is between 3.55 to 17.01 according to relative valuation methord.
Relative Value
Fair Zone
3.55-17.01
Current Price：4.67
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.28
P/B
Median3y
1.75
Median5y
2.38
5.50
FCF Yield
Median3y
-0.77
Median5y
-1.17
Competitors Valuation Multiple
The average P/S ratio for LFST's competitors is 1.34, providing a benchmark for relative valuation. LifeStance Health Group Inc Corp (LFST) exhibits a P/S ratio of 1.28, which is -4.58% above the industry average. Given its robust revenue growth of 10.83%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is LifeStance Health Group Inc (LFST) currently overvalued or undervalued?
What is LifeStance Health Group Inc (LFST) fair value?
How does LFST's valuation metrics compare to the industry average?
What is the current P/B ratio for LifeStance Health Group Inc (LFST) as of Jul 08 2025?
What is the current FCF Yield for LifeStance Health Group Inc (LFST) as of Jul 08 2025?
What is the current Forward P/E ratio for LifeStance Health Group Inc (LFST) as of Jul 08 2025?